Related Experiment Video
Updated: Jan 18, 2026
Isolation and Functional Assessment of Human Breast Cancer Stem Cells from Cell and Tissue Samples
Published on: October 2, 2020
Biomimetic Nanodrug Prepared by Cell Exocytosis Induces Cancer Stem Cell Differentiation by Attenuating Wnt Signaling
Juncai Zhang1, Jinchao Zhang1, Leyao Kang1
1State Key Laboratory of New Pharmaceutical Preparations and Excipients, Key Laboratory of Medicinal Chemistry and Molecular Diagnosis of the Ministry of Education, Laboratory of Chemical Biology of Hebei Province & College of Chemistry and Materials Science, Hebei University, Baoding, 071002, P. R. China.
Abstract:
Cancer stem cells (CSCs) represent a critical therapeutic target due to their role in chemoresistance and tumor recurrence. Targeting CSCs based on their distinct differentiation ability is a brilliant cancer therapeutic strategy. Although a few small-molecule and nanomaterial-based differentiation inducers have been reported, their limited specificity raises concerns about off-target effects, particularly the unintended differentiation of normal stem cells. Recently, mesenchymal stem cell-derived exosomes (MSC-exos) have come into focus as drug carriers as they retain parental properties that can alter functionality of CSCs types and produce mature tumor cells. Herein, an in situ biosynthetic MSC-exos-based nanodrug (E-DDP@MSNs) have been developed by incubating MSCs with cisplatin-loaded mesoporous silica nanoparticles, which are then isolated from the cell culture medium by ultracentrifugation. In contrast to the electroporation, E-DDP@MSNs retain the exosomal contents more completely without significant leakage that can promote the CSCs to differentiate into mature tumor cells, which are more susceptible to chemotherapy. Mechanistically, E-DDP@MSN promotes the differentiation of CSCs by transporting exosomal DKK-1 into CSCs, thereby causing attenuation of the Wnt pathway that is essential in maintaining stemness, self-renewal, and tumorigenicity of CSCs. In summary, E-DDP@MSNs represent a promising approach for CSC-targeted differentiation therapy, offering high efficacy with minimal toxicity.
Insights
This study developed a novel nanodrug using mesenchymal stem cell-derived exosomes loaded with cisplatin. This approach effectively targets cancer stem cells, promoting their differentiation into mature cells for enhanced chemotherapy sensitivity.
Area of Science:
- Biomedical Engineering
- Cancer Biology
- Nanotechnology
Background:
- Cancer stem cells (CSCs) drive chemoresistance and tumor recurrence, making them a key therapeutic target.
- Current CSC differentiation therapies face challenges with specificity and off-target effects on normal stem cells.
- Mesenchymal stem cell-derived exosomes (MSC-exos) show promise as targeted drug carriers due to their ability to modify CSC function.
Purpose of the Study:
- To develop and evaluate an in situ biosynthetic exosome-based nanodrug for CSC-targeted differentiation therapy.
- To investigate the mechanism by which the nanodrug induces CSC differentiation and enhances chemosensitivity.
- To assess the efficacy and safety profile of the novel nanodrug approach.
Main Methods:
- In situ biosynthesis of cisplatin-loaded MSC-exos (E-DDP@MSNs) by incubating MSCs with drug-loaded nanoparticles.
- Isolation of E-DDP@MSNs via ultracentrifugation, preserving exosomal content.
- Assessment of CSC differentiation induction, Wnt pathway attenuation, and chemosensitivity enhancement.
Main Results:
- E-DDP@MSNs effectively promoted CSC differentiation into mature tumor cells, increasing their susceptibility to chemotherapy.
- The nanodrug mechanism involves the delivery of exosomal DKK-1, leading to Wnt pathway attenuation.
- Compared to electroporation, E-DDP@MSNs demonstrated superior retention of exosomal contents and efficacy.
Conclusions:
- E-DDP@MSNs represent a promising strategy for CSC-targeted differentiation therapy.
- This approach offers high therapeutic efficacy with potentially minimal toxicity.
- The study highlights the potential of MSC-exos as drug carriers for cancer treatment.
Related Concept Videos
02:40Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
01:41Non-Canonical Wnt Signaling Pathways
02:54Canonical Wnt Signaling Pathway
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...